Lantheus (LNTH) Competitors

Lantheus has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Lantheus has a net margin of 18.05% compared to Moderna's net margin of -143.55%. Lantheus' return on equity of 29.32% beat Moderna's return on equity.

Moderna has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market.

75.3% of Moderna shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Moderna had 8 more articles in the media than Lantheus. MarketBeat recorded 15 mentions for Moderna and 7 mentions for Lantheus. Lantheus' average media sentiment score of 1.50 beat Moderna's score of 0.56 indicating that Lantheus is being referred to more favorably in the news media.

Moderna currently has a consensus target price of $40.00, suggesting a potential downside of 26.02%. Lantheus has a consensus target price of $110.43, suggesting a potential upside of 5.35%. Given Lantheus' stronger consensus rating and higher probable upside, analysts plainly believe Lantheus is more favorable than Moderna.

Insmed currently has a consensus price target of $209.13, indicating a potential upside of 95.60%. Lantheus has a consensus price target of $110.43, indicating a potential upside of 5.35%. Given Insmed's stronger consensus rating and higher possible upside, equities research analysts clearly believe Insmed is more favorable than Lantheus.

Lantheus has a net margin of 18.05% compared to Insmed's net margin of -144.44%. Lantheus' return on equity of 29.32% beat Insmed's return on equity.

In the previous week, Insmed had 12 more articles in the media than Lantheus. MarketBeat recorded 19 mentions for Insmed and 7 mentions for Lantheus. Lantheus' average media sentiment score of 1.50 beat Insmed's score of 1.01 indicating that Lantheus is being referred to more favorably in the news media.

99.1% of Lantheus shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lantheus has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Insmed has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

Lantheus has a net margin of 18.05% compared to BioNTech's net margin of -44.39%. Lantheus' return on equity of 29.32% beat BioNTech's return on equity.

99.1% of Lantheus shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, BioNTech had 3 more articles in the media than Lantheus. MarketBeat recorded 10 mentions for BioNTech and 7 mentions for Lantheus. Lantheus' average media sentiment score of 1.50 beat BioNTech's score of 1.09 indicating that Lantheus is being referred to more favorably in the media.

Lantheus has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

Lantheus currently has a consensus target price of $110.43, suggesting a potential upside of 5.35%. BioNTech has a consensus target price of $129.13, suggesting a potential upside of 44.55%. Given BioNTech's stronger consensus rating and higher probable upside, analysts clearly believe BioNTech is more favorable than Lantheus.

Lantheus has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Lantheus has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lantheus has a net margin of 18.05% compared to Viatris' net margin of -2.04%. Lantheus' return on equity of 29.32% beat Viatris' return on equity.

Viatris has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

In the previous week, Lantheus had 3 more articles in the media than Viatris. MarketBeat recorded 7 mentions for Lantheus and 4 mentions for Viatris. Lantheus' average media sentiment score of 1.50 beat Viatris' score of 0.47 indicating that Lantheus is being referred to more favorably in the news media.

Viatris presently has a consensus price target of $17.50, indicating a potential upside of 1.51%. Lantheus has a consensus price target of $110.43, indicating a potential upside of 5.35%. Given Lantheus' stronger consensus rating and higher probable upside, analysts plainly believe Lantheus is more favorable than Viatris.